Phase 3 trials of anti-COVID drug Molnupiravir begins
The Hindu
‘Pre-clinical trials showed remarkable reduction in SARS-COV-2 load’
Yashoda Hospitals, Somajiguda, in association with Natco Pharma announced the commencement of oral administration of Molnupiravir phase III clinical trials for patients with mild and moderate COVID-19 symptoms, following the nod of the Drugs Controller General of India on Friday. The clinical trials will entail the COVID patient volunteers to take 400 mg twice a day without being admitted in hospital since it is an out-patient department-based clinical trial, and have regular interactions with their physicians on day 5, day 10 and day 15 for their follow-up cycle at the hospital.More Related News

The draft policy for “Responsible Digital Use Among Students”, released on Monday by the Department of Health and Family Welfare, has recommended that parents set structured routines with clear screen-time rules and prioritise privacy, safety, and open conversation with children on digital well-being.












